Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average (2016 - 2025)

Historic Equity Average for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Q4 2025 value amounting to $95.7 million.

  • Enanta Pharmaceuticals' Equity Average fell 2049.7% to $95.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $95.7 million, marking a year-over-year decrease of 2049.7%. This contributed to the annual value of $96.8 million for FY2025, which is 4399.32% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Equity Average stood at $95.7 million, which was down 2049.7% from $72.0 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Equity Average's 5-year high stood at $444.0 million during Q1 2021, with a 5-year trough of $72.0 million in Q3 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Equity Average had a median value of $240.4 million in 2023 and averaged $247.7 million.
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 828.8% in 2021, then plummeted by 4815.23% in 2025.
  • Enanta Pharmaceuticals' Equity Average (Quarter) stood at $391.9 million in 2021, then decreased by 20.62% to $311.1 million in 2022, then crashed by 34.32% to $204.3 million in 2023, then plummeted by 41.11% to $120.3 million in 2024, then fell by 20.5% to $95.7 million in 2025.
  • Its Equity Average was $95.7 million in Q4 2025, compared to $72.0 million in Q3 2025 and $86.4 million in Q2 2025.